| Abstrakt: |
Type 2 diabetes is a significant burden on the healthcare system with unique challenges in the value-based payment system. Although there are a variety of antidiabetic medications with clinical benefit, access to newer treatments are often limited in value-based settings due to cost, availability, and insurance coverage. Thiazolidinediones (TZDs) are glucose-lowering medications indicated for the management of type 2 diabetes that are often overlooked in therapy. These insulin sensitizing medications lower blood glucose and are less costly than other antidiabetic agents. Although concerns regarding safety issues and side effects of TZDs has limited their use in current practice, evidence-based guidelines still recommend pioglitazone in select patients and its use remains important. Pioglitazone should be prioritized in patients with a history of stroke or who have high risk of stroke and atherosclerotic cardiovascular disease (ASCVD), or patients on antidiabetic therapy who require additional A1c lowering. Pioglitazone should be avoided in patients with heart failure, edema, obesity, low bone mineral density, and a history of bladder cancer. This article discusses advantages and disadvantages of pioglitazone therapy, selecting patients who may be candidates for pioglitazone therapy, and considerations for prescribing in value-based settings. [ABSTRACT FROM AUTHOR] |
Full text from SpringerLink